secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2026-08-05T11:41:04+00:00
Accession:  0001790340-26-000088
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports 17.3mo OS in pancreatic cancer; Q2 net loss $17.3M
----------------------------------------------------------------------

- Net loss of $17.3M ($0.27/share) in Q2 2026 vs $14.4M ($0.40/share) in Q2 2025; R&D expenses rose to $14.0M from $10.5M.
- Cash, equivalents and marketable securities $182.7M as of June 30, 2026, down from $217.0M at Dec 31, 2025; runway into 2029.
- Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer is dosing patients; over 30 study locations posted.
- Phase 2a data at ASCO showed 17.3-month median overall survival in 55 patients; 84% weight stable or gained weight at 3 months.
- Appointed Andrew Gengos as CFO; he previously served as CFO of Terns Pharmaceuticals (acquired by Merck for $6.7B).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/0001790340-26-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001790340-26-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer